BR112021023906A2 - Método para fornecer administração segura de um anticorpo anti-cd40 - Google Patents

Método para fornecer administração segura de um anticorpo anti-cd40

Info

Publication number
BR112021023906A2
BR112021023906A2 BR112021023906A BR112021023906A BR112021023906A2 BR 112021023906 A2 BR112021023906 A2 BR 112021023906A2 BR 112021023906 A BR112021023906 A BR 112021023906A BR 112021023906 A BR112021023906 A BR 112021023906A BR 112021023906 A2 BR112021023906 A2 BR 112021023906A2
Authority
BR
Brazil
Prior art keywords
antibody
safe administration
providing safe
administration
safe
Prior art date
Application number
BR112021023906A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Streit
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112021023906A2 publication Critical patent/BR112021023906A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112021023906A 2019-05-28 2020-05-27 Método para fornecer administração segura de um anticorpo anti-cd40 BR112021023906A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853488P 2019-05-28 2019-05-28
PCT/IB2020/055023 WO2020240434A1 (en) 2019-05-28 2020-05-27 Method of providing safe administration of an anti-cd40 antibody

Publications (1)

Publication Number Publication Date
BR112021023906A2 true BR112021023906A2 (pt) 2022-01-25

Family

ID=70918772

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023906A BR112021023906A2 (pt) 2019-05-28 2020-05-27 Método para fornecer administração segura de um anticorpo anti-cd40

Country Status (13)

Country Link
US (1) US20230174658A1 (https=)
EP (1) EP3976651A1 (https=)
JP (2) JP7755999B2 (https=)
KR (1) KR20220012918A (https=)
CN (1) CN113939535A (https=)
AU (1) AU2020284706A1 (https=)
BR (1) BR112021023906A2 (https=)
CA (1) CA3142226A1 (https=)
IL (1) IL288288A (https=)
MA (1) MA56027A (https=)
MX (1) MX2021014572A (https=)
SG (1) SG11202112909SA (https=)
WO (1) WO2020240434A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122355A2 (en) * 2021-12-24 2023-06-29 Sapience Therapeutics, Inc. Methods of treating or preventing infusion-related reactions
TW202342057A (zh) * 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用egfr/met雙特異性抗體治療之患者的輸注相關反應之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003557A1 (en) * 2005-04-21 2007-01-04 Andres Forero Method for treating cancer using premedication
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
CA2957146A1 (en) * 2014-08-12 2016-02-18 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies
WO2018160917A1 (en) 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer

Also Published As

Publication number Publication date
WO2020240434A1 (en) 2020-12-03
CN113939535A (zh) 2022-01-14
JP2022534494A (ja) 2022-08-01
MX2021014572A (es) 2022-03-17
KR20220012918A (ko) 2022-02-04
IL288288A (en) 2022-01-01
AU2020284706A1 (en) 2021-12-16
EP3976651A1 (en) 2022-04-06
JP2026004525A (ja) 2026-01-14
MA56027A (fr) 2022-04-06
US20230174658A1 (en) 2023-06-08
JP7755999B2 (ja) 2025-10-17
SG11202112909SA (en) 2021-12-30
CA3142226A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
CL2023000095A1 (es) Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos
AR128748A2 (es) Compuestos sustituidos de aminopurina, sus composiciones y métodos de tratamiento con ellos
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
EA201891983A8 (ru) Комбинированная терапия антителами к cd73
MX2021004007A (es) Moduladores de linfocitos t reguladores multivalentes.
CR20190124A (es) Inhibidores de ssao de aminopirimidina
BR112018002499A2 (pt) método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
EP4321513A3 (en) Pyrrolotriazine compounds as tam inhibitors
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
AU2016276316B2 (en) Nuclear receptor modulators
NZ728636A (en) Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
MY202135A (en) Uses of neuroactive compounds
EA201790337A1 (ru) Кристаллические формы ингибиторов глутаминазы
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MX380191B (es) Combinaciones de modalidades para el tratamiento de la diabetes.
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
BR112019002560A2 (pt) composto, composição farmacêutica, uso de um composto, e, método
MX2024008671A (es) Metodos de tratamiento de infecciones micobacterianas usando compuestos de tetraciclina.
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
EA201690763A1 (ru) Лечение рака поджелудочной железы
BR112016020556A8 (pt) compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto
BR112021023906A2 (pt) Método para fornecer administração segura de um anticorpo anti-cd40